Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).

remission
blast cells
leukemia
anthracyclines
daunorubicin
  • 116 views
  • 03 Jun, 2021
  • 41 locations
Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not …

flt3 internal tandem duplication
cytarabine
induction chemotherapy
cancer
hematologic malignancy
  • 39 views
  • 15 Apr, 2021
  • 39 locations
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

CC-90009-AML-002 is an exploratory Phase 1b open-label multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in subjects with acute myeloid

flt3 internal tandem duplication
venetoclax
refractory acute myeloid leukemia (aml)
azacitidine
hydroxyurea
  • 12 views
  • 26 May, 2021
  • 14 locations
An Open-Label Multicenter Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML

decitabine
cytarabine
cancer
refractory acute myeloid leukemia (aml)
  • 2 views
  • 27 Jan, 2021
  • 27 locations
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 24 Jan, 2021
  • 2 locations
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.

refractory acute myeloid leukemia (aml)
  • 71 views
  • 28 Jan, 2021
  • 18 locations
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients …

flow cytometry
cytarabine
venetoclax
cancer
consolidation therapy
  • 3 views
  • 03 Jun, 2021
  • 21 locations
TL-895 and KRT-232 Study in Acute Myeloid Leukemia

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for …

TP53
tyrosine
  • 0 views
  • 22 May, 2021
  • 7 locations
A Trial to Evaluate the Safety and Efficacy of oNKord in Subjects With Acute Myeloid Leukemia

WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord in 33 adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable

transplant conditioning
induction chemotherapy
remission
hematologic disorder
acute promyelocytic leukemia
  • 0 views
  • 24 May, 2021
  • 8 locations
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

  • 0 views
  • 13 May, 2021
  • 1 location